The deal with China’s Chimagen Biosciences is the latest example of pharma interest in exploring the potential of “T cell engagers” in autoimmune disease.

Pharmaceutical giant GSK has struck a deal worth up to 1.4 billion US dollars (£1.1 billion) to buy asthma drug firm Aiolos Bio. The takeover of the three-month-old start-up is part of GSK’s ...

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

GSK (NYSE:GSK) said on Tuesday that it will acquire clinical-stage biopharmaceutical company Aiolos Bio for a $1B upfront payment and up to $400M on achieving certain regulatory milestones.

The Orifices -- Where Most of Medicine's Money Is Made Over the course of a long career, Dr Lundberg has witnessed huge, even astounding advances in what he calls orificial medicine.

The move follows phase 1/2 results with SK bio's GBP510, which found that it stimulated ... subject to data and regulatory review," said GSK in a statement this morning. COVAX is a World Health ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker's settlement with ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

(Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused ...

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

Settlement resolves 80,000 or 93% of pending US cases GSK top gainer on FTSE-100, best one-day gain since Dec 2022 To record 1.8 billion pounds charge in Q3 results Oct 10 (Reuters) - GSK (GSK.L ...